Results
2308
All the companies in the healthcare sector, including healthcare provider and equipment, healthcare tech, pharmaceuticals, biotech and life sciences.
2,308 companies
kneat.com
Market Cap: CA$637.2m
Designs, develops, and supplies software for data and document management within regulated environments in North America, Europe, and the Asia Pacific.
KSI
CA$6.75
7D
1.2%
1Y
63.8%
Altimmune
Market Cap: US$452.6m
A clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.
ALT
US$5.58
7D
-7.2%
1Y
-30.6%
Paragon Care
Market Cap: AU$703.5m
Distributes medical equipment, devices, and consumable products in Australia, New Zealand, and Asia.
PGC
AU$0.42
7D
-2.3%
1Y
n/a
Bioventus
Market Cap: US$450.6m
A medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally.
BVS
US$6.79
7D
0.7%
1Y
9.0%
Claritev
Market Cap: US$450.0m
Provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States.
CTEV
US$27.38
7D
25.5%
1Y
25.3%
REGENXBIO
Market Cap: US$445.9m
A clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
RGNX
US$8.89
7D
11.5%
1Y
-44.0%
Cullinan Therapeutics
Market Cap: US$442.6m
A clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States.
CGEM
US$7.50
7D
-5.2%
1Y
-68.7%
Septerna
Market Cap: US$438.5m
A clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.
SEPN
US$9.84
7D
41.0%
1Y
n/a
Zenas BioPharma
Market Cap: US$438.0m
A clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies.
ZBIO
US$10.47
7D
7.5%
1Y
n/a
Personalis
Market Cap: US$437.2m
Develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
PSNL
US$4.95
7D
-2.9%
1Y
239.0%
Capricor Therapeutics
Market Cap: US$431.5m
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$9.44
7D
32.8%
1Y
49.8%
Sage Therapeutics
Market Cap: US$431.5m
A biopharmaceutical company, develops and commercializes brain health medicines.
SAGE
US$6.89
7D
2.1%
1Y
-38.4%
Amylyx Pharmaceuticals
Market Cap: US$431.4m
A clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
AMLX
US$4.84
7D
5.2%
1Y
163.0%
Precigen
Market Cap: US$428.0m
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$1.45
7D
5.8%
1Y
4.3%
SIGA Technologies
Market Cap: US$427.9m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$5.99
7D
0.8%
1Y
-20.7%
Tourmaline Bio
Market Cap: US$425.4m
Operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases.
TRML
US$16.56
7D
4.9%
1Y
13.7%
Oxford Biomedica
Market Cap: UK£320.1m
A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
OXB
UK£3.02
7D
2.4%
1Y
-7.4%
Treace Medical Concepts
Market Cap: US$422.7m
A medical technology company, designs, manufactures, and markets medical devices in the United States.
TMCI
US$6.72
7D
-6.6%
1Y
36.0%
EyePoint Pharmaceuticals
Market Cap: US$421.8m
Engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
EYPT
US$6.13
7D
4.8%
1Y
-49.5%
PureTech Health
Market Cap: UK£314.2m
Engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.
PRTC
UK£1.31
7D
6.2%
1Y
-42.8%
Verastem
Market Cap: US$417.1m
A development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.
VSTM
US$7.59
7D
4.1%
1Y
-34.6%
Northwest Biotherapeutics
Market Cap: US$416.6m
A biotechnology company, focuses on developing personalized immune therapies for cancer.
NWBO
US$0.29
7D
0.4%
1Y
-36.8%
Knight Therapeutics
Market Cap: CA$577.8m
Focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America.
GUD
CA$5.80
7D
-1.0%
1Y
-5.1%
Verve Therapeutics
Market Cap: US$412.7m
A clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States.
VERV
US$4.63
7D
6.4%
1Y
-22.2%
Standard BioTools
Market Cap: US$410.2m
Develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific.
LAB
US$1.08
7D
-6.9%
1Y
-58.1%
Surmodics
Market Cap: US$408.7m
Provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally.
SRDX
US$28.58
7D
5.5%
1Y
-18.5%
Vitalhub
Market Cap: CA$569.0m
Provides technology and software solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally.
VHI
CA$10.20
7D
-4.5%
1Y
45.3%
Maze Therapeutics
Market Cap: US$405.1m
A clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States.
MAZE
US$9.25
7D
-8.7%
1Y
n/a
Fortrea Holdings
Market Cap: US$402.0m
A contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide.
FTRE
US$4.44
7D
-14.5%
1Y
-83.5%
Celcuity
Market Cap: US$401.8m
A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
CELC
US$10.61
7D
-0.6%
1Y
-36.8%
MeiraGTx Holdings
Market Cap: US$401.0m
A clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases.
MGTX
US$4.99
7D
-11.2%
1Y
-9.9%
Sana Biotechnology
Market Cap: US$393.6m
A biotechnology company, focuses on utilizing engineered cells as medicines in the United States.
SANA
US$1.75
7D
-12.8%
1Y
-79.8%
Tectonic Therapeutic
Market Cap: US$391.9m
A biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs).
TECX
US$20.99
7D
1.4%
1Y
n/a
Organogenesis Holdings
Market Cap: US$390.7m
A regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States.
ORGO
US$3.08
7D
3.2%
1Y
11.2%
Australian Clinical Labs
Market Cap: AU$609.0m
Provides pathology diagnostic services in Australia.
ACL
AU$3.10
7D
2.6%
1Y
33.6%
Prothena
Market Cap: US$386.5m
A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States.
PRTA
US$7.18
7D
-5.7%
1Y
-68.3%